Clinical trials: HIV Antibodies
HIV Infections
Testing of INSTI™ HIV-1 Antibody Test Kit in Volunteer Subjects at Risk for HIV Infection
Each year up to 22 million persons in the US are tested for HIV. Currently available "rapid" tests do not provide test results for at least 30 minutes from the collection of serum and plasma from the subject.
- Trial name
- NCT00514605
- Testing
- Behavioral counseling, HIV-1 Antibody Test Kit
- Where
- 14 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in South Africa.
- Trial name
- ENABLE 1 (NCT07655128)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl)
- Volunteers
- 87 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV Infections
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America…
- Trial name
- NCT02716675
- Testing
- VRC01
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 2,699 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, Geriatric Medicine
COVID-19 Serology and Immunosenescence
This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors.
- Conditions
- Covid19, Geriatric Medicine, Seroconversion, Immunosenescence
- Trial name
- SERO-CoV-OLD (NCT04563650)
- Testing
- blood sample
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
HIV, Herpes Simplex Infections
Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV
The purpose of this study is to assess the safety and pharmacokinetics of MB66, a monoclonal antibody film for vaginal application that is being developed to potentially reduce the transmission of herpes simplex virus (HSV) and…
- Trial name
- VAST (NCT02579083)
- Testing
- MB66
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- KBio Inc
HIV
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
HVTN 206/HPTN 114 is a randomized, double blind, controlled, phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing…
- Trial name
- NCT06812494
- Testing
- VRC07-523LS 400mg, PGT121.414.LS 400mg, PGDM1400LS 400mg
- Where
- 17 sites in United States, Brazil and 1 more
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Giant Lymph Node Hyperplasia
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy.
- Trial name
- NCT00127569
- Testing
- Rituximab
- Volunteers
- 25 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
Trimer 4571 is a vaccine designed to stimulate the development of broadly neutralizing antibodies (bnAbs) against HIV. Trimer 4571 is investigational, meaning it is not approved by the US Food and Drug Administration (FDA).
- Trial name
- NETI (NCT04985760)
- Testing
- Trimer 4571 vaccine 100mcg with 500mcg alum adjuvant, Trimer 4571 vaccine 500mcg with 500mcg alum adjuvant
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Madhu Chhanda Choudhary
HIV-1 Infection, HIV Infection
DCVax Plus Poly ICLC in Healthy Volunteers
DCVax-001 is a recombinant protein vaccine designed to prevent and potentially treat human immunodeficiency virus (HIV) infection.
- Conditions
- HIV-1 Infection, HIV Infection, Healthy Volunteers
- Trial name
- NCT01127464
- Testing
- DCVax-001, Poly-ICLC
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults
The purpose of this study is to evaluate the safety, tolerability, and serum concentrations of a human monoclonal antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), administered in multiple doses and routes to healthy, HIV-uninfected…
- Trial name
- NCT03387150
- Testing
- VRC07-523LS
- Where
- 7 sites in United States, Switzerland
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus (HIV)
Romidepsin Plus 3BNC117 Phase 2a Study
The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.
- Trial name
- ROADMAP (NCT02850016)
- Testing
- 3BNC117, Romidepsin
- Where
- 3 sites in United States, Denmark and 1 more
- Volunteers
- 48 people
- Sponsor
- Rockefeller University
Human Immunodeficiency Virus
3BNC117 and 10-1074 in HIV Uninfected Adults
This is a phase 1 clinical trial to evaluate the safety and pharmacokinetics of the highly neutralizing anti-human immunodeficiency virus-1 monoclonal antibodies 3BNC117 and 10-1074, when given in combination, in human…
- Trial name
- NCT02824536
- Testing
- 3BNC117, 10-1074
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
HIV Infections
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered via intravenous infusion…
- Trial name
- NCT03928821
- Testing
- PGT121, PGDM1400, 10-1074
- Where
- 4 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects
The purpose of this study is to assess the safety and tolerability of intravaginal administration of P2G12. 11 subjects will receive P2G12/placebo. Three subjects in Group 1 will receive up to 7mg of P2G12, or placebo.
- Trial name
- NCT01403792
- Testing
- P2G12
- Where
- United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Surrey
Human Immunodeficiency Virus (HIV)
3BNC117 and 10-1074 in HIV-infected Individuals
This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074…
- Trial name
- NCT02825797
- Testing
- 3BNC117, 10-1074, Analytical treatment interruption
- Where
- 2 sites in United States, Germany
- Volunteers
- 34 people
- Sponsor
- Rockefeller University
HIV Infections
A Study to Monitor Patients With Primary or Early HIV Infection
The purpose of this study is to monitor patients who recently have been infected with HIV in order to learn how their immune systems respond to HIV infection and to study how the virus acts in their bodies.
- Trial name
- NCT00000911
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
MMR Vaccination Among HIV-infected Adults
This is a prevalence study of protective antibodies to measles, mumps, and rubella (MMR) in HIV-infected adults and HIV-uninfected controls.
- Trial name
- NCT02724852
- Testing
- 0.5 ml of MMR vaccine
- Where
- Thailand
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Chiang Mai University
HIV
Combination Therapy With 3BNC117 and 10-1074 in HIV-Infected Individuals
Background: Human immunodeficiency virus (HIV) affects the immune system. The main function of the immune system is protect you from infections and other diseases such as cancer.
- Trial name
- NCT03571204
- Testing
- 3BNC117 and 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants
An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed…
- Trial name
- SPAN (NCT05291520)
- Testing
- VH3810109, rHuPH20
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
The purpose of this study is to assess the tolerability, adherence and efficacy of single tablet dolutegravir/abacavir/lamivudine antiretroviral therapy in people living with HIV with a history of injection drug use (IDU)…
- Trial name
- TAISTR (NCT02659761)
- Testing
- dolutegravir/abacavir/lamivudine
- Where
- Ireland
- Volunteers
- 33 people
- Sponsor
- University College Dublin